The first patient has been treated in what has been named the Sandpiper Trial. The Phase I/II clinical trial will evaluate a therapy that combines a novel oncolytic viral immunotherapy agent called MG1-MAGEA3 with pembrolizumab, which is an approved checkpoint inhibitor. The Sandpiper Trial will study the use of this combination therapy in patients with non-small cell lung cancer who are no longer responding to chemotherapy.
The MG1-MAGEA3 agent was developed by Ontario researchers and is now being taken to market by spinoff company Turnstone Biologics. OICR is providing support to the trial through a grant. The trial is currently open at two sites, The Ottawa Hospital and the Juravinski Cancer Centre in Hamilton. More information for patients can be found at the links below.
Read the news release: First patient treated in Turnstone’s lung cancer trial combining novel viral cancer therapy with approved checkpoint inhibitor